| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Entera Bio Ltd (NASDAQ: ENTX)
ENTX Technical Analysis
5
| As on 9th Jun 2023 ENTX STOCK Price closed @ 0.85 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 1.88 & Strong Sell for SHORT-TERM with Stoploss of 2.50 we also expect STOCK to react on Following IMPORTANT LEVELS. |
ENTXSTOCK Price
| Open | 0.80 | Change | Price | % |
| High | 0.89 | 1 Day | 0.05 | 6.25 |
| Low | 0.80 | 1 Week | 0.06 | 7.59 |
| Close | 0.85 | 1 Month | 0.15 | 21.43 |
| Volume | 21970 | 1 Year | -2.30 | -73.02 |
| 52 Week High 3.23 | 52 Week Low 0.50 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| ENTX Daily Charts |
ENTX Intraday Charts |
Whats New @ Bazaartrend |
ENTX Free Analysis |
|
|
ENTX Important Levels Intraday
| RESISTANCE | 1.02 |
| RESISTANCE | 0.97 |
| RESISTANCE | 0.93 |
| RESISTANCE | 0.90 |
| SUPPORT | 0.80 |
| SUPPORT | 0.77 |
| SUPPORT | 0.73 |
| SUPPORT | 0.68 |
ENTX Forecast May 2024
| 4th UP Forecast | 2.76 |
| 3rd UP Forecast | 2.15 |
| 2nd UP Forecast | 1.77 |
| 1st UP Forecast | 1.39 |
| 1st DOWN Forecast | 0.31 |
| 2nd DOWN Forecast | -0.07 |
| 3rd DOWN Forecast | -0.45 |
| 4th DOWN Forecast | -1.06 |
ENTX Weekly Forecast
| 4th UP Forecast | 2.06 |
| 3rd UP Forecast | 1.67 |
| 2nd UP Forecast | 1.43 |
| 1st UP Forecast | 1.19 |
| 1st DOWN Forecast | 0.51 |
| 2nd DOWN Forecast | 0.27 |
| 3rd DOWN Forecast | 0.03 |
| 4th DOWN Forecast | -0.36 |
ENTX Forecast2024
| 4th UP Forecast | 6.71 |
| 3rd UP Forecast | 4.83 |
| 2nd UP Forecast | 3.67 |
| 1st UP Forecast | 2.51 |
| 1st DOWN Forecast | -0.81 |
| 2nd DOWN Forecast | -1.97 |
| 3rd DOWN Forecast | -3.13 |
| 4th DOWN Forecast | -5.01 |
Entera Bio Ltd ( NASDAQ USA Symbol : ENTX )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
ENTX Business Profile
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, an oral parathyroid hormone product candidate, which is in Phase 2 clinical trials for the treatment of hypoparathyroidism; and EB613 that is in Phase 2 clinical trials for the treatment of osteoporosis. It is also developing EB613 for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel. Address: Kiryat Hadassah Minrav Building, Jerusalem, Israel, 9122002
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service